CoChat

Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study

Šoupal, Jan, Petruželková, Lenka, Grunberger, George, Hásková, Aneta, Flekač, Milan, Matoulek, Martin, Mikeš, Ondřej, Pelcl, Tomáš, Škrha, Jan, Horová, Eva, Škrha, Jan, Parkin, Christopher G., Svačina, Štěpán, Prázný, Martin · 2020 · Diabetes Care

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: This study assessed the clinical impact of four treatment strategies in adults with type 1 diabetes (T1D): real-time continuous glucose monitoring (rtCGM) with multiple daily insulin injections (rtCGM+MDI), rtCGM with continuous subcutaneous insulin infusion (rtCGM+CSII), self-monitoring of blood glucose with MDI (SMBG+MDI), and SMBG with CSII (SMBG+CSII). RESEARCH DESIGN AND METHODS: This 3-year, nonrandomized, prospective, real-world, clinical trial followed 94 participants with T1D (rtCGM+MDI, n = 22; rtCGM+CSII, n = 26; SMBG+MDI, n = 21; SMBG+CSII, n = 25). The main end points were changes in A1C, time in range (70–180 mg/dL [3.9–10 mmol/L]), time below range (<70 mg/dL [<3.9 mmol/L]), glycemic variability, and incidence of hypoglycemia. RESULTS: At 3 years, the rtCGM groups (rtCGM+MDI and rtCGM+CSII) had significantly lower A1C (7.0% [53 mmol/mol], P = 0.0002, and 6.9% [52 mmol/mol], P < 0.0001, respectively), compared with the SMBG+CSII and SMBG+MDI groups (7.7% [61 mmol/mol], P = 0.3574, and 8.0% [64 mmol/mol], P = 1.000, respectively), with no significant difference between the rtCGM groups. Significant improvements in percentage of time in range were observed in the rtCGM subgroups (rtCGM+MDI, 48.7–69.0%, P < 0.0001; and rtCGM+CSII, 50.9–72.3%, P < 0.0001) and in the SMBG+CSII group (50.6–57.8%, P = 0.0114). Significant reductions in time below range were found only in the rtCGM subgroups (rtCGM+MDI, 9.4–5.5%, P = 0.0387; and rtCGM+CSII, 9.0–5.3%, P = 0.0235). Seven severe hypoglycemia episodes occurred: SMBG groups, n = 5; sensor-augmented insulin regimen groups, n = 2. CONCLUSIONS: rtCGM was superior to SMBG in reducing A1C, hypoglycemia, and other end points in individuals with T1D regardless of their insulin delivery method. rtCGM+MDI can be considered an equivalent but lower-cost alternative to sensor-augmented insulin pump therapy and superior to treatment with SMBG+MDI or SMBG+CSII therapy.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc19-0888

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

Metadata

Authors
Šoupal, J., Petruželková, L., Grunberger, G., Hásková, A., Flekač, M., Matoulek, M., Mikeš, O., Pelcl, T., Škrha, J., Horová, E., Škrha, J., Parkin, C. G., Svačina, Š., & Prázný, M.
Affiliations
  • Charles University (CZ)
  • Oakland University (US)
  • 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
  • CGParkin Communications, Inc., Henderson, NV
Corresponding author
Šoupal, Jan
Venue
Diabetes Care
Published
2019-09-17
Volume
43
Issue
1
Pages
37-43
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2974459507
Cited by
242
References
25
Citations by year
2026: 14 · 2025: 21 · 2024: 42 · 2023: 30 · 2022: 50 · 2021: 46 · 2020: 35 · 2019: 4
FWCI
27.48
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
type 1 diabetes, continuous glucose monitoring, insulin pump therapy, multiple daily insulin injections, self-monitoring of blood glucose, glycemic control, HbA1c, time in range, time below range, glycemic variability, hypoglycemia, adults with type 1 diabetes, insulin delivery method, real-world evidence
MeSH terms
Adult, Blood Glucose, Diabetes Mellitus, Type 1, Drug Administration Routes, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Insulin Infusion Systems, Longitudinal Studies, Male, Middle Aged, Blood Glucose Self-Monitoring, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.